GSK 679586

Drug Profile

GSK 679586

Alternative Names: 679586; GSK679586; GSK679586A

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 06 May 2010 GlaxoSmithKline completes enrolment in the phase II 106870 trial in Asthma in USA, South Africa, European Union & Norway
  • 21 Jan 2008 Phase I development is ongoing
  • 01 Nov 2006 Phase-I clinical trials in Asthma in Australia (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top